IL17A and rheumatoid arthritis: IL-17, produced locally in RA joints, exacerbates inflammation by triggering synovial cells and chondrocytes to release pro-inflammatory mediators, upregulating MMPs production, and enhancing RANKL expression, thereby accelerating cartilage and bone destruction [33].